{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:47:15Z","timestamp":1740149235363,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12272-020-01245-y","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T20:03:42Z","timestamp":1594757022000},"page":"714-723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of the von Willebrand factor\/factor VIII complex produced by a novel purification process"],"prefix":"10.1007","volume":"43","author":[{"given":"Jee Won","family":"Ahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Sun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You Jin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So Ra","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baik L.","family":"Seong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2100-2502","authenticated-orcid":false,"given":"Suk Hoon","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"key":"1245_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1586\/17474086.2014.899896","volume":"7","author":"L Aledort","year":"2014","unstructured":"Aledort L, Ljung R, Mann K, Pipe S (2014) Factor VIII therapy for hemophilia A: current and future issues. Expert Rev Hematol 7:373\u2013385. https:\/\/doi.org\/10.1586\/17474086.2014.899896","journal-title":"Expert Rev Hematol"},{"key":"1245_CR2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/hae.12494","volume":"20","author":"MI Bravo","year":"2014","unstructured":"Bravo MI, Da Rocha-Souto B, Grancha S, Jorquera JI (2014) Native plasma-derived FVIII\/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors. Haemophilia 20:905\u2013911. https:\/\/doi.org\/10.1111\/hae.12494","journal-title":"Haemophilia"},{"key":"1245_CR3","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1111\/hae.12975","volume":"22","author":"MI Bravo","year":"2016","unstructured":"Bravo MI, Ortiz AM, Costa M, Grancha S, Jorquera JI (2016) Neutralizing capacity of inhibitors on FVIII is lower for natural FVIII\/VWF complex than for isolated FVIII: in vitro comparative study in eleven different therapeutic FVIII concentrates. Haemophilia 22:e301\u2013e348. https:\/\/doi.org\/10.1111\/hae.12975","journal-title":"Haemophilia"},{"key":"1245_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1055\/s-2006-949668","volume":"32","author":"U Budde","year":"2006","unstructured":"Budde U, Metzner HJ, M\u00fcller HG (2006) Comparative analysis and classification of Von Willebrand factor\/factor VIII concentrates: impact on treatment of patients with Von Willebrand disease. Semin Thromb Hemost 32:626\u2013635. https:\/\/doi.org\/10.1055\/s-2006-949668","journal-title":"Semin Thromb Hemost"},{"key":"1245_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0165-022X(01)00221-4","volume":"49","author":"T Burnouf","year":"2001","unstructured":"Burnouf T, Radosevich M (2001) Affinity chromatography in the industrial purification of plasma proteins for therapeutic use. J Biochem Biophys Methods 49:575\u2013586. https:\/\/doi.org\/10.1016\/S0165-022X(01)00221-4","journal-title":"J Biochem Biophys Methods"},{"key":"1245_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1423-0410.1991.tb00864.x","volume":"60","author":"T Burnouf","year":"1991","unstructured":"Burnouf T, Burnouf-Radosevich M, Huart JJ, Goudemand M (1991) A high purified factor VIII: concentrate prepared from cryoprecipitate by ion-exchange chromatography. Vox Sang 60:8\u201315. https:\/\/doi.org\/10.1111\/j.1423-0410.1991.tb00864.x","journal-title":"Vox Sang"},{"key":"1245_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/2040620717721458","volume":"8","author":"LA Cafuir","year":"2017","unstructured":"Cafuir LA, Kempton CL (2017) Current and emerging factor VIII replacement products for hemophilia A. Ther Adv Hematol 8:303\u2013313. https:\/\/doi.org\/10.1177\/2040620717721458","journal-title":"Ther Adv Hematol"},{"key":"1245_CR7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2147\/TCRM.S87543","volume":"12","author":"G Castaman","year":"2016","unstructured":"Castaman G, Linari S (2016) Human von Willebrand factor\/factor VIII concentrates in the management of pediatric patients with con Willebrand disease\/hemophilia A. Ther Clin Risk Manag 12:1029\u20131037. https:\/\/doi.org\/10.2147\/TCRM.S87543","journal-title":"Ther Clin Risk Manag"},{"key":"1245_CR8","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood-2014-08-528398","volume":"125","author":"NG Christopher","year":"2015","unstructured":"Christopher NG, Motto DG, Paola JD (2015) Diagnostic approach to von Willebrand disease. Blood 125:2029\u20132037. https:\/\/doi.org\/10.1182\/blood-2014-08-528398","journal-title":"Blood"},{"key":"1245_CR9","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/S0049-3848(08)70003-3","volume":"9","author":"G Di Minno","year":"2011","unstructured":"Di Minno G, Coppola A (2011) A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors? Blood Transfus 9:S14\u2013S20. https:\/\/doi.org\/10.1016\/S0049-3848(08)70003-3","journal-title":"Blood Transfus"},{"key":"1245_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2516.2011.02608.x","volume":"18","author":"T Elm","year":"2012","unstructured":"Elm T, Karpf DM, \u00d8vlisen K, Pelzer H, Ezban M, Tranholm Kjalke M (2012) Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophlia A mice. Haemophilia 18:139\u2013145. https:\/\/doi.org\/10.1111\/j.1365-2516.2011.02608.x","journal-title":"Haemophilia"},{"key":"1245_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1160\/TH10-03-0151","volume":"104","author":"M Franchini","year":"2010","unstructured":"Franchini M, Lippi G (2010) Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review. Thromb Haemost 104:931\u2013940. https:\/\/doi.org\/10.1160\/TH10-03-0151","journal-title":"Thromb Haemost"},{"key":"1245_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.thromres.2018.05.027","volume":"168","author":"I Garagiola","year":"2018","unstructured":"Garagiola I, Palla R, Peyvandi F (2018) Risk factors for inhibitor development in severe hemophilia A. Thromb Res 168:20\u201327. https:\/\/doi.org\/10.1016\/j.thromres.2018.05.027","journal-title":"Thromb Res"},{"key":"1245_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1055\/s-0038-1651071","volume":"57","author":"VS Hornsey","year":"1987","unstructured":"Hornsey VS, Griffin BD, Pepper DS, Micklem LR, Prowse CV (1987) Immunoaffinity purification of factor VIII complex. Thromb Haemost 57:102\u2013105. https:\/\/doi.org\/10.1055\/s-0038-1651071","journal-title":"Thromb Haemost"},{"key":"1245_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2008-06-160432","volume":"113","author":"CL Kempton","year":"2009","unstructured":"Kempton CL, Gilbert C, White II (2009) How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 113:11\u201317. https:\/\/doi.org\/10.1182\/blood-2008-06-160432","journal-title":"Blood"},{"key":"1245_CR15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.transci.2018.07.012","volume":"57","author":"B Kevane","year":"2018","unstructured":"Kevane B, O\u2019Connell N (2018) The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A. Transfus Apheresis Sci 57:502\u2013506. https:\/\/doi.org\/10.1016\/j.transci.2018.07.012","journal-title":"Transfus Apheresis Sci"},{"key":"1245_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/00365519950185526","volume":"59","author":"HA Kleinveld","year":"1999","unstructured":"Kleinveld HA, Andersson N-E, van Voorthuizen H, den Hartog J, de Groot PG (1999) Determination of coagulation factor VIII activity by a chromogenic substrate method on STA, an automated coagulation analyzer. Scand J Clin Lab Investig 59:335\u2013341. https:\/\/doi.org\/10.1080\/00365519950185526","journal-title":"Scand J Clin Lab Investig"},{"key":"1245_CR17","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/S0049-3848(08)70003-3","volume":"122","author":"W Kreuz","year":"2008","unstructured":"Kreuz W (2008) The role of VWF for the success of immune tolerance induction. Thromb Res 122:S7\u2013S12. https:\/\/doi.org\/10.1016\/S0049-3848(08)70003-3","journal-title":"Thromb Res"},{"key":"1245_CR18","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1182\/blood-2016-11-750885","volume":"129","author":"J Lai","year":"2017","unstructured":"Lai J, Hough C, Tarrant J, Lillicrap D (2017) Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood 129:3147\u20133154. https:\/\/doi.org\/10.1182\/blood-2016-11-750885","journal-title":"Blood"},{"key":"1245_CR19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/ajh.21739","volume":"85","author":"MR Ledford-Kraemer","year":"2010","unstructured":"Ledford-Kraemer MR (2010) Analysis of von Willebrand factor structure by multimer analysis. Am J Hematol 85:510\u2013514. https:\/\/doi.org\/10.1002\/ajh.21739","journal-title":"Am J Hematol"},{"key":"1245_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2516.2004.00893.x","volume":"10","author":"S Lethagen","year":"2004","unstructured":"Lethagen S, Carlson M, Hillarp A (2004) A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 10:243\u2013249. https:\/\/doi.org\/10.1111\/j.1365-2516.2004.00893.x","journal-title":"Haemophilia"},{"key":"1245_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/hae.13239","volume":"23","author":"M Makris","year":"2017","unstructured":"Makris M, Kessler CM (2017) SIPPET Trial: the answers. Haemophilia 23:344\u2013345. https:\/\/doi.org\/10.1111\/hae.13239","journal-title":"Haemophilia"},{"key":"1245_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1046\/j.1365-2516.1998.0040s3025.x","volume":"4","author":"HJ Metzner","year":"1998","unstructured":"Metzner HJ, Hermentin P, Cuesta-Linker T, Langner S, M\u00fcller HG, Friedebold J (1998) Characterization of factor VIII\/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis. Haemophilia 4:25\u201332. https:\/\/doi.org\/10.1046\/j.1365-2516.1998.0040s3025.x","journal-title":"Haemophilia"},{"key":"1245_CR24","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/jth.13888","volume":"16","author":"F Peyvandi","year":"2018","unstructured":"Peyvandi F, Cannav\u00f2 A, Garagiola I, Palla R, Mannucci PM, Rosendall FR (2018) Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost 16:778\u2013790. https:\/\/doi.org\/10.1111\/jth.13888","journal-title":"J Thromb Haemost"},{"key":"1245_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/rth2.12166","volume":"3","author":"A Riddell","year":"2019","unstructured":"Riddell A, Vinayagam S, Gomez K, Laffan M, McKinnon T (2019) Evaluation of von Willebrand factor concentrates by platelet adhesion to collagen using an in vitro flow assay. Res Pract Thromb Haemost 3:126\u2013135. https:\/\/doi.org\/10.1002\/rth2.12166","journal-title":"Res Pract Thromb Haemost"},{"key":"1245_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1055\/s-2007-994004","volume":"19","author":"JP Scott","year":"1993","unstructured":"Scott JP, Montgomery RR (1993) Therapy of von Willebrand disease. Semin Thromb Hemost 19:37\u201347. https:\/\/doi.org\/10.1055\/s-2007-994004","journal-title":"Semin Thromb Hemost"},{"key":"1245_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1046\/j.1365-2141.2002.03845.x","volume":"119","author":"PC Spiegel Jr","year":"2002","unstructured":"Spiegel PC Jr, Stoddard BL (2002) Optimization of factor VIII replacement therapy: can structural studied help in evading antibody inhibitors? Br J Haematol 119:310\u2013322. https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03845.x","journal-title":"Br J Haematol"},{"key":"1245_CR28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.biologicals.2005.11.010","volume":"34","author":"M Stadler","year":"2006","unstructured":"Stadler M, Gruber G, Kannicht C, Biesert L, Ranomski KU, Suhartono H, Pock K, Neisser-Svae A, Weinberger J, R\u00f6misch J, Svae TE (2006) Characterization of a novel high-purity, double virus inactivated von Willebrand factor and factor VIII concentrate (Wilate). Biologicals 34:281\u2013288. https:\/\/doi.org\/10.1016\/j.biologicals.2005.11.010","journal-title":"Biologicals"},{"key":"1245_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/MBC.0000000000000065","volume":"25","author":"M Stockschlaeder","year":"2014","unstructured":"Stockschlaeder M, Schneppenheim R, Budde U (2014) Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis 25:206\u2013216. https:\/\/doi.org\/10.1097\/MBC.0000000000000065","journal-title":"Blood Coagul Fibrinolysis"},{"key":"1245_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/2040620712464509","volume":"4","author":"C Witmer","year":"2013","unstructured":"Witmer C, Young G (2013) Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 4:59\u201372. https:\/\/doi.org\/10.1177\/2040620712464509","journal-title":"Ther Adv Hematol"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-020-01245-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-020-01245-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-020-01245-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:14:34Z","timestamp":1626221674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-020-01245-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1245"],"URL":"https:\/\/doi.org\/10.1007\/s12272-020-01245-y","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"type":"print","value":"0253-6269"},{"type":"electronic","value":"1976-3786"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"22 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"J W. Ahn, E. S. Chang, Y. J. Jung, S. R. Kim, and S. H. Ha are salaried employees of GC Pharma. There are no other conflicts of interest to be declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}